We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

AIM ImmunoTech Inc (AIM) USD0.001

Sell:$0.48 Buy:$0.50 Change: $0.0772 (13.74%)
Market closed |  Prices as at close on 15 April 2024 | Switch to live prices |
Sell:$0.48
Buy:$0.50
Change: $0.0772 (13.74%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 15 April 2024 | Switch to live prices |
Sell:$0.48
Buy:$0.50
Change: $0.0772 (13.74%)
Market closed |  Prices as at close on 15 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.

Contact details

Address:
2117 SW Highway 484
OCALA
34473-7949
United States
Telephone:
+1 (352) 4487797
Website:
https://aimimmuno.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
AIM
ISIN:
US00901B1052
Market cap:
$28.04 million
Shares in issue:
49.90 million
Sector:
Biotechnology
Exchange:
-
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Thomas Equels
    President, Chief Executive Officer, Executive Vice Chairman
  • Robert Dickey
    Chief Financial Officer
  • Peter Rodino
    Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Secretary
  • David Strayer
    Chief Scientific and Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.